Madison Vaccines Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Madison Vaccines Inc.
The sector still attracts the attention of clinical investigators and the pharmaceutical industry, despite disappointing results from another clinical-stage candidate.
Madison Vaccines Inc. is developing two candidates for prostate cancer: MVI-816 trains the patient’s immune system to recognize and attack the cancer as a foreign body by targeting a molecule called prostatic acid phosphatase (PAP), which is uniquely displayed on the surface of prostate cancer cells. Madison Vaccines’ second product, MVI-118, targets cells that over-express the androgen receptor.
This month’s profile group, Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky, features profiles of EnBiotix, Nosopharm, and Spero Therapeutics. Plus these Start-Ups Across Health Care: Elute, Madison Vaccines, Monarch Medical Technologies, Niveus Medical, and SolaranRx.
The money raised in Series A financings for biopharma, medtech, and diagnostics start-ups is down 8% from the same period last year, but the number of deals is down even more dramatically.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Gene Therapy, Cell Therapy
- Large Molecule